



Respite in pain

A new lease of life for pelvic cancer patients

With the launch of regenerative nutraceutical AKTOCYTE tablets.

As part of sustained efforts for ensuring affordable cancer care availability to a wider cross section of the society, the constituent units of Department of Atomic Energy have joined hands to address the requirements of pelvic cancer patients. BARC, ACTREC and TMH came out with a new and highly effective drug formulation to provide pelvic cancer patients a new lease of life.

The newly launched AKTOCYTE tablets - a joint effort of DAE bodies - can now address radiotherapy-induced side effects in pelvic cancer patients, thereby ensuring better quality of life to patients in the long run. The tablets are designed to function as an adjuvant to cancer radiotherapy, and are poised to play the role of a regenerative nutraceutical, immunomodulator, and as an antioxidant.

Prior to its commercial launch, AKTOCYTE has proven its worth during rigorous clinical trials, and was accorded approval by the Food Safety and Standards Authority of India.

Speaking on the launch of AKTOCYTE, Shri Vivek Bhasin, Director, BARC appreciated the efforts of DAE scientists and the private industry for the successful commercialization of AKTOCYTE. Dr. Ajit Kumar Mohanty, Secretary, DAE and Chairman, AEC hailed it as a continuation of DAE's efforts in ensuring the health security of the country and expressed satisfaction that it was happening in the Platinum Jubilee Year of the department.

Bengaluru based M/s. IDRS Labs Pvt. Ltd., collaborated with DAE in the release of AKTOCYTE tablets.

The newly launched AKTOCYTE tablets - a joint effort of BARC, ACTREC and TMH - can now address radiotherapy-induced side effects in pelvic cancer patients, thereby ensuring better quality of life to patients in the long run. The tablets are designed to function as an adjuvant to cancer radiotherapy, and are poised to play the role of a regenerative nutraceutical, immunomodulator, and as an antioxidant.